Lung Transplant Indications and Considerations

Disease-Specific Indications

• The American Thoracic Society recommends lung transplantation for patients with chronic obstructive pulmonary disease (COPD) who have a BODE index of 5-6, PaCO₂ >50 mmHg, and/or PaO₂ <60 mmHg, with the goal of improving survival and quality of life 1
• The American Thoracic Society suggests listing COPD patients for transplantation when they have a BODE index >7, FEV₁ <15-20% predicted, or three or more severe exacerbations in the preceding year, as these factors indicate a high risk of mortality 1
• The American College of Chest Physicians recommends lung transplantation for patients with idiopathic pulmonary fibrosis (IPF) as it demonstrates a survival benefit with 5-year survival rates of 50-56% 2, 3
• The American Thoracic Society recommends referral of IPF patients for lung transplantation based on diffusion capacity decline, presence of progressive disease despite optimal medical management, severe functional impairment with oxygen dependency, and deteriorating physiologic course 2, 3, 4
• The European Respiratory Society suggests lung transplantation for patients with cystic fibrosis, with post-transplant survival showing 85% at 1 year and 45% at 5 years 5, 6
• The European Respiratory Society recommends transplant referral for bronchiectasis patients aged ≤65 years with FEV₁ <30% and significant clinical instability, or rapid progressive respiratory deterioration despite optimal medical management 6

General Transplant Considerations

• The International Society for Heart and Lung Transplantation (ISHLT) criteria should be used to evaluate patients with pulmonary arterial hypertension for lung transplantation, as it represents a valid indication for lung transplantation with demonstrated survival benefit 7
• The ISHLT criteria should also be used to evaluate patients with pulmonary alveolar proteinosis (PAP) for lung transplantation, as it is suggested for PAP patients progressing despite whole lung lavage and/or pharmacological treatment 7
• The American Academy of Allergy, Asthma, and Immunology recommends considering lung transplantation for patients with primary immunodeficiency with agammaglobulinemia and life-threatening chronic lung disease 8

Critical Timing Considerations

• Early referral to a transplant center is essential, given the scarcity of donor organs and prolonged waiting times, with the goal of listing patients early enough to avoid extreme disability or pre-transplant death 4

Lung Transplant Selection Criteria and Disease‑Specific Eligibility

Selection Process

• The selection process for lung transplantation applies the same eligibility criteria for both primary transplantation and re‑transplantation, ensuring consistent assessment across all candidates. 9
• Candidates must satisfy the International Society for Heart and Lung Transplantation (ISHLT) disease‑specific criteria (e.g., for COPD, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, pulmonary alveolar proteinosis, etc.) before being listed for transplant. 10

Disease‑Specific Eligibility (as defined by ISHLT)

• For each underlying lung disease, ISHLT provides distinct threshold parameters (such as severe airflow limitation for COPD, rapid decline in diffusion capacity for idiopathic pulmonary fibrosis, or refractory pulmonary hypertension) that must be met to qualify for listing. 10

Note: The cited references do not specify the strength of evidence; they are presented as guideline statements from the European Respiratory Journal.